Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol

Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL... Abstract Context Real-world evidence of the relationship between high triglyceride (TG) levels and increased cardiovascular disease (CVD) risk among statin-treated patients with LDL cholesterol (LDL-C) control is lacking. Objective We aimed to compare the risk of CVD and mortality between patients with high vs. normal TGs. Design Longitudinal observational cohort study. Setting Integrated delivery system. Patients Patients aged >45 whose TG level was either <150 mg/dL (normal) or between 200-499 mg/dL (high) in 2010, were taking only statins, had LDL-C values 40-100 mg/dL, and had diagnosed CVD. Methods Patients were followed through December 2016. Our primary outcomes were a composite of non-fatal MI, non-fatal stroke, unstable angina, coronary revascularization, and all-cause mortality, and a second composite adding peripheral revascularization and aneurysm repair. We compared multivariable adjusted incidence rates and rate ratios (RR) of the outcomes and their components. Results A total of 14,481 patients comprised the normal TG group and 2,702 patients were in the high TG group. Multivariable adjusted incidence of the second composite was 10% greater in the high TG group (50.9/1,000 person-years, 95% CI 47.0-55.2 vs. 46.5, 44.8-48.2, RR 1.10, 95% CI 1.00-1.20, p=0.041). The difference was driven by non-fatal MI (RR 1.20, 95% CI 1.00-1.45, p=0.045), coronary revascularization (RR 1.18, 95% CI 1.00-1.40, p=0.045) and peripheral revascularization (RR 1.56, 95% CI 1.14-2.13, p=0.006). Conclusions CVD risk in statin-treated patients was associated with high TG levels. Ongoing CV outcome trials of add-on therapies in statin treated high-risk patients with high TG levels are testing this hypothesis. Copyright © 2018 Endocrine Society http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Endocrinology and Metabolism Oxford University Press

Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol

Loading next page...
 
/lp/ou_press/increased-cardiovascular-risk-in-hypertriglyceridemic-patients-with-U3RetfWmBT
Publisher
Endocrine Society
Copyright
Copyright © 2018 Endocrine Society
ISSN
0021-972X
eISSN
1945-7197
D.O.I.
10.1210/jc.2018-00470
Publisher site
See Article on Publisher Site

Abstract

Abstract Context Real-world evidence of the relationship between high triglyceride (TG) levels and increased cardiovascular disease (CVD) risk among statin-treated patients with LDL cholesterol (LDL-C) control is lacking. Objective We aimed to compare the risk of CVD and mortality between patients with high vs. normal TGs. Design Longitudinal observational cohort study. Setting Integrated delivery system. Patients Patients aged >45 whose TG level was either <150 mg/dL (normal) or between 200-499 mg/dL (high) in 2010, were taking only statins, had LDL-C values 40-100 mg/dL, and had diagnosed CVD. Methods Patients were followed through December 2016. Our primary outcomes were a composite of non-fatal MI, non-fatal stroke, unstable angina, coronary revascularization, and all-cause mortality, and a second composite adding peripheral revascularization and aneurysm repair. We compared multivariable adjusted incidence rates and rate ratios (RR) of the outcomes and their components. Results A total of 14,481 patients comprised the normal TG group and 2,702 patients were in the high TG group. Multivariable adjusted incidence of the second composite was 10% greater in the high TG group (50.9/1,000 person-years, 95% CI 47.0-55.2 vs. 46.5, 44.8-48.2, RR 1.10, 95% CI 1.00-1.20, p=0.041). The difference was driven by non-fatal MI (RR 1.20, 95% CI 1.00-1.45, p=0.045), coronary revascularization (RR 1.18, 95% CI 1.00-1.40, p=0.045) and peripheral revascularization (RR 1.56, 95% CI 1.14-2.13, p=0.006). Conclusions CVD risk in statin-treated patients was associated with high TG levels. Ongoing CV outcome trials of add-on therapies in statin treated high-risk patients with high TG levels are testing this hypothesis. Copyright © 2018 Endocrine Society

Journal

Journal of Clinical Endocrinology and MetabolismOxford University Press

Published: May 29, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off